Effective Binding of a Phosphatidylserine-Targeting Antibody to Ebola Virus Infected Cells and Purified Virions
Ebola virus is responsible for causing severe hemorrhagic fevers, with case fatality rates of up to 90%. Currently, no antiviral or vaccine is licensed against Ebola virus. A phosphatidylserine-targeting antibody (PGN401, bavituximab) has previously been shown to have broad-spectrum antiviral activi...
Saved in:
Main Authors: | S. D. Dowall, V. A. Graham, K. Corbin-Lickfett, C. Empig, K. Schlunegger, C. B. Bruce, L. Easterbrook, R. Hewson |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/2015/347903 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Anti-Ebola virus mAb 3A6 protects highly viremic animals from fatal outcome via binding GP(1,2) in a position elevated from the virion membrane
by: Kathryn M. Hastie, et al.
Published: (2025-02-01) -
The Potential of Antibodies Against the Phosphatidylserine / Prothrombin Complex as a Biomarker in Antiphospholipid Syndrome
by: Piotr Pasek, et al.
Published: (2025-02-01) -
Measuring Response to Therapy by Near-Infrared Imaging of Tumors Using a Phosphatidylserine-Targeting Antibody Fragment
by: Jian Gong, et al.
Published: (2013-06-01) -
Ebola Virus and SARS-CoV-2: Similarities and Differences
by: Robert C. SIZEMORE, et al.
Published: (2020-07-01) -
Mathematical Modelling of the Transmission of Ebola Virus in Human Populations in Uganda.
by: Nkamuhabwa, Jolly
Published: (2024)